Form 8-K · Current report
Alexandria Real Estate Equities 8-K, filed Aug 3, 2026
- Filed
- CIK
- 0001035443
- Accession no.
- 0001035443-26-000067
Summary
Alexandria Real Estate Equities filed a Form 8-K on August 3, 2026, furnishing its second-quarter 2026 earnings press release and supplemental information, and said it is on track for annualized fourth-quarter 2026 leverage guidance of 5.6x to 6.2x. The company reported delivering a 426,927-rentable-square-foot R&D facility in June 2026 leased to Bristol Myers Squibb under a 15-year lease, and scheduled an earnings conference call for August 4, 2026.
Key points
- Alexandria reported second-quarter results for the period ended June 30, 2026, with supplemental information posted on its website.
- The company cited $3.6 billion of liquidity and a weighted-average remaining debt term of 9.7 years, with 95.7% fixed-rate debt since 2022.
- Alexandria delivered a 426,927 RSF R&D facility for Bristol Myers Squibb in June 2026 under a 15-year lease, intended to support research in cancer, immune-mediated and neurodegenerative diseases.
- Fourth-quarter 2026 annualized guidance was given as 5.6x to 6.2x net debt and preferred stock to adjusted EBITDA and 3.6x to 4.1x fixed-charge coverage.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
Items reported
- 2.02Results of Operations and Financial Condition
- 9.01Financial Statements and Exhibits
From the filing
Item 2.02. Results of Operations and Financial Condition. On August 3, 2026, Alexandria Real Estate Equities, Inc. (the “Company”) issued a press release entitled “Alexandria Real Estate Equities, Inc. Reports Second Quarter Ended June 30, 2026 Financial and Operating Results.” The press release referred to certain supplemental information that is available on the Company’s website at www.are.com. A copy of the press release and supplemental information are attached hereto as Exhibit 99.1. …
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.